在先进的固体瘤患者中对莫纳利祖马布加杜尔瓦卢马布进行1/2期研究
Sandip P Patel1, Teresa Alonso-Gordoa2, Susana Banerjee3
1University of California San Diego, Moores Cancer Center, San Diego, California, USA spatel@ucsd.edu.
Journal for immunotherapy of cancer
|February 3, 2024
概括
莫纳利祖马布与杜尔瓦卢马布结合,在先进的固体瘤中显示出有前途的免疫激活,具有可管理的安全性. 需要进一步的研究来优化这种免疫疗法组合,以增强抗瘤反应.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 临床试验 临床试验
背景情况:
- 研究将莫纳利祖马布 (抗NKG2A/CD94) 与杜尔瓦卢马布 (抗PD-L1) 结合起来,以增强抗瘤免疫力的协同潜力.
- 针对先天性 (通过NKG2A) 和自适应性 (通过PD-L1) 免疫路径,可以克服瘤耐药性.
研究的目的:
- 在患有晚期固体瘤的患者中评估莫纳利祖马布加杜尔瓦卢马布组合的安全性和耐受性.
- 评估这种新型免疫治疗方案的抗瘤活性和药理动力学.
主要方法:
- 这是一项1/2期临床试验,该试验招募了先前未接受免疫治疗的患有先进固体瘤的患者 (ECOG 0-1).
- 第1部分涉及莫纳利祖马布与固定的杜尔瓦卢马布的剂量升级;第2部分涉及特定癌症类型 (宫癌,MSS-CRC,NSCLC,子宫内膜癌,卵巢癌) 的剂量扩大.
- 通过不良事件评估安全性;用RECIST v1.1测量抗瘤活性;探索性分析侧重于免疫细胞激活和TME.
主要成果:
- 该组合耐受良好,没有发现剂量限制性毒性或最大耐受剂量.
- 常见的不良事件包括疲劳,喘息和腹.
- 在扩张队列中观察到适度的反应率,显著的免疫激活包括持续的NK细胞激活,CD8+T细胞增殖和TME中免疫细胞透的增加.
结论:
- 莫纳利祖马布加杜尔瓦卢马布显示出良好的安全性,并在周围血液和瘤微环境中诱导显著的免疫激活.
- 虽然直接的临床疗效是温和的,但观察到的免疫调节效应表明这种组合在特定患者群体中的潜力.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.3K
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...